


## Supplemental data

**Table S1. WES data output.**

	Proband
WES enrichment kit	Agilent SureSelect Human All Exon V7
Total passing quality filters unique reads	144,793,449
Target regions coverage >10x	91.2%
Target regions coverage >20x	90.0%
Average sequencing depth on target	157x
Private and low frequency variants with functional effect <sup>1</sup>	252
Putative disease genes [AD trait] <sup>2</sup>	5 <sup>3</sup>
- candidate genes	0
Putative disease genes [AR/X-linked trait] <sup>2</sup>	4 <sup>4</sup>
- candidate genes	1, <i>TUB</i>

<sup>1</sup>Private or low frequency [gnomAD MAF<0.1% and recurrence <1% within our ~2,500 exomes database] non-synonymous single nucleotide variants or indels within coding exons and splice regions [-3/+8].

<sup>2</sup>Functional impact assessed by Combined Annotation Dependent Depletion [CADD] v.1.6 [<http://cadd.gs.washington.edu/>], Mendelian Clinically Applicable Pathogenicity [M-CAP] v.1.0 [<http://bejerano.stanford.edu/mcap/>] and InterVar [<http://wintervar.wglab.org>] v2.0.1. Variants predicted as benign or likely benign by InterVar were discarded and only those with CADD score>20 or M-CAP score>0.025 were retained. 3BBS4 [c.857T>C; p.Met286Thr], VPS13B [c.4786C>T; p.Leu1596Phe], IRX5 [c.760G>A; p.Glu254Lys], DRD4 [c.719G>C; p.Gly240Ala], LAMA1 [c.1745C>T; p.Ala582Val].



**Figure S1. Lipid analysis in control and patient fibroblasts.**

Analysis of neutral lipids were performed by high-performance thin-layer chromatography [HPTLC] using the appropriate solvent mixture. As standards [Std], free cholesterol, cholesterol ester, triglycerides were utilized. The position of pure standard lipids is indicated on the margin of the panel.